[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][O][C][=Branch1][C][=O][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][=Branch1][C][=O][C@H1][Branch2][Ring1][C][C][C][=C][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][/C][=Branch1][Ring1][=N][/O][/N][N][S][=Branch1][C][=O][=Branch1][C][=O][C][=C][Branch2][Ring1][Ring1][C][=C][Branch1][#Branch2][C][=C][Ring1][=Branch1][C][Branch1][C][C][C][C][Branch1][C][C][C][C][Branch1][C][C][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, 3-amidinophenylalanine-derived, second generation serine protease inhibitor prodrug targeting the human urokinase plasminogen activator (uPA) system with potential antineoplastic and antimetastatic activities. After oral administration, upamostat is converted to the active N alpha-(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(L)-phenylalanine-4-ethoxycarbonylpiperazide (WX-UK1), which inhibits several serine proteases, particularly uPA; inhibition of uPA may result in the inhibition of tumor growth and metastasis. uPA is a serine protease involved in degradation of the extracellular matrix and tumor cell migration and proliferation."}]